Keywords regulatory T cells CTLA-4 prostate cancer neoadjuvant immunotherapy CyTOF single-cell RNA sequencing tumor-associated macrophages dendritic cells Introduction To date, immune checkpoint blockade immunotherapy (ICB) has proven largely ineffective for patients with prostate cancer (PCa).1,2,3 Agents targeting the PD-1/PD-L1 pathway alone or in combination with androgen receptor inhibitors,4,5,6 chemotherapy,7 or PARP inhibition8 have failed in phase III trials.9 Similarly, CTLA-4...
ArticleVolume 7, Issue 3102638Open access Affiliations & Notes 1Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, 10032, United States of America 2Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY, 10032, United States of America 3Department of Immunology, Mayo Clinic Arizona, Phoenix, AZ, 85054, United States of America 4Department of Urology, Mayo Clinic Arizona, Phoenix,...
Where to watch Watch for free Synopsis Trailers Similar titles Subtitle languages English Video technology Dolby Vision Subtitle languages English Video technology Dolby Vision Video technology Dolby Vision Subtitle languages English Video technology Dolby Vision Video technology Dolby Vision Didn't find what you were looking for? Let us notify you once it becomes available on more services. Something wrong?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
